YI: 111 Inc Company Sales

Official company branding of 111 Inc. (YI)

The scaling of B2B services and the network effect have created a sustainable moat for 111, Inc. (YI), driving growth in the company's total sales. Stable demand for pharmaceuticals in China renders the business a defensive asset, while low cyclicality ensures resilience during crises. In this context, the 1.50 metric serves as a target level, confirming the transparency of daily revenue and the current market dynamics of product sales.

Company Total Revenue: 111 Inc (YI) for 07/04/2022 - 11/14/2026

Summary analytical data breakdowns for 111, Inc (YI)

- price and consensus price forecast:
Stock Price 111 Inc|YI - Consensus Target
- market capitalization information:
Market Valuation 111 Inc|YI - Company Buyout Price
- balance sheet equity data:
Accounting Value per Share 111, Inc.|YI - Total Stockholders' Equity|Market Capitalization to Book Value Ratio 111.com.cn|YI - Company Total Asset Base
- debt burden and liquidity indicators:
Debt to Equity 111, Inc.|YI - Long-Term Liabilities to Equity|Short-Term Debt to Capital 111 Inc|YI - Aggregate Debt Obligations|Debts to Book Capitalization 111 Inc.|YI - Company Long-Term Debts|Company Short-Term Debt 111, Inc.|Quick Liquidity 111.com.cn
- company profitability and valuation multiples indicators:
YI - Net Income|Projected Future Earnings 111, Inc.|YI - P/E Multiple|Forward P/E Multiple 111 Inc|YI - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio 111 Inc|YI - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) 111, Inc.|YI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth 111.com.cn|YI - Net earnings per share growth this year|Expected earnings per share trend next year 111, Inc.
- sales revenue and business income indicators:
YI - Revenue and Sales Volume|Company Future Sales 111 Inc|YI - Price-to-Revenue Ratio|Market Cap to Projected Revenue 111 Inc.
Initial company analysis:YI, 111.com.cn
Brand item of 111, Inc

The stable cash flow of the digital drug distribution platform 111, Inc. is confirmed through daily actual receipts from commercial activities. By analyzing the company's current sales volume, an investor sees the net amount of confirmed transactions, excluding any subjective forecasts. This metric captures the real liquidity of the business, allowing for an assessment of the operating model's resilience. The consistency of these indicators testifies to the asset's reliability and the predictability of its future earnings.

Key competitors

Revenue and Sales Volume CVS Corp|Company Sales MCK (McKesson Corporation)|Company Sales cencora.com COR|Company Gross Revenue CAH|HSIC - Company Sales|PBH (Prestige Consumer Healthcare Inc) - Company Total Revenue|WGRX - Revenue and Sales Volume|China Jo-Jo Drugstores, Inc - Company Gross Revenue|UPC (universe-pharmacy.com) - Company Revenue|Company Annual Revenue Biodexa BDRX|Revenue and Sales Volume HK Pharma Digital|BIMI International Medical (BIMI) - Company Sales Revenue|Revenue and Sales Volume jiuzhou-drugstore.com (CJJD)|Revenue and Sales Volume WBA (Walgreens Boots Alliance, Inc.)